Biosimilars Suits Likely To Remain Copious Even As Zarxio 'Patent Dance' Battle Seems Over
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Circuit denies Amgen and Sandoz petitions to rehear case; separate ongoing litigation – or even a Supreme Court appeal – could provide opening for further challenges.